期刊
CANCERS
卷 12, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/cancers12020319
关键词
colorectal cancer; biomarkers; molecular markers; early stage CRC; gene signature; clinical transition; clinical test; challenges
类别
资金
- Fondation Cancer [F1R-LSC-PAU-13HY2C]
- FNR [PoC18/12554295]
- Foundation Vera Nijs and Jens Erik Rosborg
- CORE grant [C16/BM/11282028]
Colorectal cancer (CRC) is a leading cause of death among cancer patients. This heterogeneous disease is characterized by alterations in multiple molecular pathways throughout its development. Mutations in RAS, along with the mismatch repair gene deficiency, are currently routinely tested in clinics. Such biomarkers provide information for patient risk stratification and for the choice of the best treatment options. Nevertheless, reliable and powerful prognostic markers that can identify high-risk CRC patients, who might benefit from adjuvant chemotherapy, in early stages, are currently missing. To bridge this gap, genomic information has increasingly gained interest as a potential method for determining the risk of recurrence. However, due to several limitations of gene-based signatures, these have not yet been clinically implemented. In this review, we describe the different molecular markers in clinical use for CRC, highlight new markers that might become indispensable over the next years, discuss recently developed gene expression-based tests and highlight the challenges in biomarker research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据